- Cat. No.
- A10800
Rivaroxaban
Synonyms: BAY 59-7939; Xarelto
Rivaroxaban is an oxazolidinone derivative optimized for inhibiting both free Factor Xa and Factor Xa bound in the prothrombinase complex.
Search by product name, CAS, target or catalog number. Press Down Arrow to reach product suggestions, Tab to move between links, and Escape to close suggestions.
Factor Xa inhibitors block the serine protease that converts prothrombin to thrombin in blood coagulation. Factor Xa sits where the intrinsic and extrinsic coagulation pathways converge and assembles with factor Va into the prothrombinase complex. Direct inhibitors bind the active site of free and complex-bound factor Xa without a cofactor. Rivaroxaban was described in 2005 as BAY 59-7939, an oral, direct factor Xa inhibitor. The discovery of apixaban from a pyrazolopyridine carboxamide series was reported in 2007. Edoxaban, betrixaban and otamixaban are further direct inhibitors, while RWJ-445167 blocks both factor Xa and thrombin.
Synonyms: BAY 59-7939; Xarelto
Rivaroxaban is an oxazolidinone derivative optimized for inhibiting both free Factor Xa and Factor Xa bound in the prothrombinase complex.
Synonyms: BMS-562247-01
Apixaban is an anticoagulant for the prevention of venous thromboembolism and venous thromboembolic events.
Synonyms: FXV 673
Otamixaban(FXV 673) is an intravenous direct factor Xa inhibitor.
Synonyms: DU-176b
Edoxaban is a selective factor Xa inhibitor with Ki of 0.561 nM
Synonyms: DU-176
Edoxaban(DU-176) is an oral factor Xa (FXa) inhibitor in clinical development for stroke prevention.
BMS-740808 is a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa.
Synonyms: 3DP-10017
RWJ-445167 (3DP-10017) is a dual inhibitor of thrombin and factor Xa with Ki of 4.0 nM and 230 nM, respectively, exhibiting potent antithrombotic activity.
Synonyms: PRT-054,021; PRT-054021
Betrixaban is an anticoagulant drug which acts as a direct factor Xa inhibitor. It is potent, orally active and highly selective for factor Xa, being selected from a group of similar compounds for its low hERG affinity.
Razaxaban is a selective, potent, and orally bioavailable inhibitor of coagulation factor Xa.
Out of stock
All 4 sizes
Synonyms: TAK 442
Letaxaban, also known as TAK-442, is a potent, selective, and orally active factor Xa inhibitor, which is a tetrahydropyrimidin-2(1H)-one derivative. TAK-442 inhibited endogenous FXa activity in platelet-poor human [half-maximal inhibitory concentration (IC(50)): 53 nM, TAK-442] and rat (IC(50): 32 nM, TAK-442) plasma.
DPC423 is a highly potent and orally bioavailable pyrazole antithrombotic agent.
Synonyms: Xarelto; BAY 59-7939
5-R-Rivaroxaban is (R) enantiomer of Rivaroxaban. Rivaroxaban is a novel, oral, direct Factor Xa (FXa) inhibitor in late-stage development for the prevention and treatment of thromboembolic disorders.
Synonyms: DU-176b
Edoxaban is an oral factor Xa (FXa) inhibitor in clinical development for stroke prevention.
Synonyms: PRT054021 maleate
Betrixaban maleate is a highly selective and potent inhibitor of factor Xa (fXa), demonstrating an IC50 of 1.5 nM. This compound exhibits significant antithrombotic activity, making it valuable for research into anticoagulant therapies. Betrixaban maleate is suitable for studies focused on thrombosis, cardiovascular diseases, and hemostatic regulation.
Synonyms: Fondaparinux sodium salt; PENTA; Arixtra; Xantidar; SR 90107A; IC-85158
Fondaparinux sodium is a factor Xa inhibitor to form the high affinity binding site for the anti-coagulant factor antithrombin III (ATIII).
Synonyms: Sodium chloro(4-methylbenzenesulfonyl)azanide hydrate
ChloraMine-T hydrate is a selective Factor Xa inhibitor known for its utility in synthetic chemistry. It serves as a versatile reagent in aminohydroxylation and allylic amination reactions, functioning as a nitrogen source in the aziridination of alkenes and facilitating the deprotection of sulfur groups in thiol-containing compounds. Additionally, ChloraMine-T hydrate exhibits antimicrobial properties, demonstrating efficacy against various bacterial strains, including Staphylococcus epidermidis, Staphylococcus aureus, Enterococcus faecalis, Escherichia coli, Proteus mirabilis, and Enterococcus cloacae, making it valuable for applications in both enzymatic inhibition studies and antimicrobial research.
DPC423 free base is a selectively potent Factor Xa inhibitor, demonstrating inhibition constants (Kis) of 0.15 nM in humans and 0.3 nM in rabbits. It exhibits moderate selectivity with Kis of 60 nM against human trypsin, 61 nM against plasma kallikrein, and 6000 nM against thrombin. By inhibiting the formation of the prothrombinase complex, DPC423 reduces thrombin generation, thereby obstructing fibrin formation and platelet activation. This compound is valuable for research applications related to anticoagulation in arterial thrombosis.
Out of stock
All 3 sizes
BMS-344577 is a potent, orally active factor Xa inhibitor with an IC50 of 4 nM, demonstrating significant efficacy in anticoagulation research. This compound also exhibits strong CYP3A4 inhibition with an IC50 of 0.3 μM. BMS-344577 is primarily utilized in studies related to cardiovascular disease, facilitating the exploration of therapeutic interventions targeting coagulation pathways.
Out of stock
All 3 sizes
ZK-813039 is a potent, orally active inhibitor of factor Xa, a key enzyme in the coagulation cascade. It effectively prolongs prothrombin time, making it a valuable tool in the study of anticoagulation mechanisms. This compound is primarily utilized in cardiovascular disease research, contributing to the development of novel therapeutic approaches for managing thrombotic disorders.
Out of stock
All 3 sizes
BMS-269223 is a potent and selective orally active inhibitor of factor Xa, demonstrating a Ki value of 6.5 nM and an effective concentration for 2x prothrombin time prolongation of 32 μM. This compound plays a crucial role in inhibiting thrombosis formation, making it an important tool for cardiovascular disease research. BMS-269223 facilitates the study of anticoagulant therapies and the underlying mechanisms of thrombotic disorders.
Out of stock
All 3 sizes
Synonyms: PER977
Ciraparantag is a potent inhibitor of thrombin and factor Xa, serving as a broad-spectrum reversal agent for various anticoagulants. This compound effectively neutralizes the effects of low-molecular-weight heparin, unfractionated heparin, and certain direct oral anticoagulants, while sparing vitamin K antagonists and argatroban. Its unique mechanism makes Ciraparantag a valuable tool for research focused on anticoagulation reversal and hemostasis.
Dechloro Rivaroxaban is a potent, selective inhibitor targeting Factor Xa, demonstrating a Ki of 0.4 nM against human free FXa. This compound effectively inhibits prothrombinase activity and fibrin-associated FXa activity, exhibiting IC50 values of 2.1 nM and 92 nM, respectively. Dechloro Rivaroxaban is suitable for research applications focused on coagulation and antithrombotic drug development.
Synonyms: PER977 acetate
Ciraparantag acetate is a potent inhibitor of thrombin and factor Xa, serving as a broad-spectrum reversal agent for various anticoagulants, including low molecular weight heparins, unfractionated heparins, and certain direct oral anticoagulants, excluding vitamin K antagonists (VKAs). Its primary mechanism targets the coagulation pathway, facilitating the restoration of normal hemostasis in clinical situations where anticoagulation reversal is necessary. Ciraparantag acetate is valuable in research applications focused on anticoagulation management and hemostatic balance in cardiovascular studies.
Synonyms: YM150
Darexaban is a potent, selective, orally active factor Xa (FXa) inhibitor with an IC50 of 54.6 nM. It exhibits high selectivity for FXa over related serine proteases, including trypsin, thrombin, and kallikrein. Due to its anticoagulant and antithrombotic properties, Darexaban is valuable in research related to thrombosis, cardiovascular diseases, and coagulation pathways.
Synonyms: PD-0348292
Eribaxaban is a selective inhibitor of Factor Xa (FXa) with a potent Ki value of 0.32 nM. This compound effectively reduces thrombus formation, making it a valuable tool in the study of anticoagulation mechanisms. Its oral bioavailability supports its application in various in vitro and in vivo research settings related to thrombosis and hemostasis.